Sistema de Salut de Catalunya
Institut Català de la Salut
[Banerjee S] Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK. [Gonzalez-Martin A] Gynaecology Unit, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK. [Harter P] Department of Gynaecology and Gynaecological Oncology, Ev. Kliniken Essen-Mitte, Essen, Germany. [Lorusso D] Scientific Directorate and Gynecologic Oncology Unit, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Italy. [Moore KN] Stephenson Cancer Center, University of Oklahoma, Norman, Oklahoma, USA. [Oaknin A] Servei d’Oncologia Mèdica, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2021-09-20T10:03:20Z
2021-09-20T10:03:20Z
2020-12-11
Inhibidors de PARP; Càncer d’ovari avançat
Inhibidores de PARP; Cáncer de ovario avanzado
PARP inhibitors; Advanced ovarian cancer
Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is the latest breakthrough in the management of newly diagnosed advanced ovarian cancer. The results of the SOLO-1 trial in 2018 led to European Medicines Agency and Food and Drug Administration approval of olaparib as first-line maintenance therapy in patients with BRCA1/2 mutation, establishing a new standard of care. Subsequently, the results of three phase III trials (PRIMA, PAOLA-1, VELIA) evaluating the use of first-line PARP inhibitors beyond patients with BRCA1/2 mutations and as combination strategies were presented in 2019, leading to the recent approval of maintenance niraparib irrespective of biomarker status and olaparib in combination with bevacizumab in homologous recombination deficiency-positive-associated advanced ovarian cancer. An ESMO Open - Cancer Horizons round-table expert panel discussed the four phase III trials of first-line PARP inhibitor therapy and how they are changing the clinical management of advanced ovarian cancer.
The project is supported by an unrestricted educational grant from AstraZeneca. The authors received an honorarium for their participation in the round table from BMJ.
Article
Published version
English
Ovaris - Càncer -Tractament; Inhibidors enzimàtics - Ús terapèutic; DISEASES::Neoplasms::Neoplasms by Site::Endocrine Gland Neoplasms::Ovarian Neoplasms; CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Molecular Mechanisms of Pharmacological Action::Enzyme Inhibitors::Poly(ADP-ribose) Polymerase Inhibitors; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de las glándulas endocrinas::neoplasias ováricas; COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::mecanismos moleculares de acción farmacológica::inhibidores enzimáticos::inhibidores de poli(ADP-ribosa) polimerasas
BMJ
ESMO Open;5
https://doi.org/10.1136/esmoopen-2020-001110
Attribution-NonCommercial 4.0 International
http://creativecommons.org/licenses/by-nc/4.0/
